多款罕见病“救命药”可报销

Core Insights - The theme for this year's International Rare Disease Day is "Not Just Rare," highlighting the importance of addressing rare diseases and improving access to treatment [1] Group 1: Policy Changes - The new national medical insurance drug list and the first commercial health insurance innovative drug list were implemented in January, allowing reimbursement for critical drugs for rare diseases like neuroblastoma [1][2] - The inclusion of drugs for six rare diseases, including neuroblastoma, short bowel syndrome, and Gaucher disease, in the first commercial insurance list marks a significant policy shift [2] Group 2: Treatment Advancements - Neuroblastoma, a common rare disease with an incidence rate of approximately 7.72 per million, has a high-risk group comprising over 50% of cases, with a five-year survival rate of less than 50% [1] - The drug Naxitamab injection can increase the survival rate of high-risk neuroblastoma patients from 50% to between 65% and 70%, recognized as an effective treatment method [1] - The new national medical insurance list added four new rare disease drugs, bringing the total number of rare disease medications to over 100, covering more than 50 disease types [2] Group 3: Financial Impact - The high cost of treatment previously deterred many families, with a single treatment cycle for a 15 kg child costing approximately 150,000 yuan, requiring at least five cycles [2] - With the new policy, the reimbursement rate for Naxitamab injection exceeds 30%, providing financial relief to families [2] - The inclusion of the innovative drug Toripalimab for melanoma in the national medical insurance list can save patients 50% to 70% on treatment costs, reducing annual expenses from about 42,000 yuan to approximately 13,000 yuan [2]